Caricamento...
Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
Human EGF Receptor 2 (HER2) is an important oncogene driving aggressive metastatic growth in up to 20% of breast cancer tumors. At the same time, it presents a target for passive immunotherapy such as trastuzumab (TZM). Although TZM has been widely used clinically since 1998, not all eligible patien...
Salvato in:
| Pubblicato in: | Molecules |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7767145/ https://ncbi.nlm.nih.gov/pubmed/33348564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules25245976 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|